Literature DB >> 9630839

Underproduction of interleukin-12 in susceptible mice during progressive leishmaniasis is due to decreased CD40 activity.

F P Heinzel1, R M Rerko, A M Hujer.   

Abstract

Interleukin-12 promotes Th1 lymphocyte responses necessary for the cure of murine Leishmania major infection. We found that IL-12 p40 mRNA expression peaked at 4 weeks of infection in resistant C57BL/6 mice at levels threefold greater than in BALB/c mice. Peak IL-12 p40 expression in both strains was reduced threefold following treatment with neutralizing anti-CD40 ligand antibody and disease worsened in C57BL/6 mice. Direct activation of cultured lymph node cells by anti-CD40 MAb or soluble CD40 ligand failed to restore deficient IL-12 production by infected BALB/c mice unless recombinant IFN-beta was added to culture. Infected BALB/c lymph nodes also contained two- to threefold fewer low-density CD40+ accessory cells compared to that in C57BL/6 mice. We conclude that CD40-dependent responses are continually required for healing of leishmaniasis and that progressive disease is associated with decreased CD40-stimulated IL-12 synthesis as a consequence of either altered cytokine environment or inadequate accessory cell number.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9630839     DOI: 10.1006/cimm.1998.1267

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  23 in total

1.  CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury.

Authors:  Guohong Li; John M Sanders; Melissa H Bevard; Zhiqi Sun; James W Chumley; Elena V Galkina; Klaus Ley; Ian J Sarembock
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

Review 2.  Sex hormones and modulation of immunity against leishmaniasis.

Authors:  Heidi Snider; Claudio Lezama-Davila; James Alexander; Abhay R Satoskar
Journal:  Neuroimmunomodulation       Date:  2009-02-11       Impact factor: 2.492

3.  Antigenic dietary protein guides maturation of the host immune system promoting resistance to Leishmania major infection in C57BL/6 mice.

Authors:  Joana F Amaral; Ana C Gomes-Santos; Josiely Paula-Silva; Jacques R Nicoli; Leda Q Vieira; Ana M C Faria; Juscilene S Menezes
Journal:  Immunology       Date:  2009-12-02       Impact factor: 7.397

4.  Pretreatment with recombinant Flt3 ligand partially protects against progressive cutaneous leishmaniasis in susceptible BALB/c mice.

Authors:  I B Kremer; M P Gould; K D Cooper; F P Heinzel
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

5.  Influence of costimulatory molecules on immune response to Leishmania major by human cells in vitro.

Authors:  C I Brodskyn; G K DeKrey; R G Titus
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

6.  Transfection of Trypanosoma cruzi with host CD40 ligand results in improved control of parasite infection.

Authors:  Mustapha Chamekh; Vincent Vercruysse; Mohammed Habib; Maxime Lorent; Michel Goldman; Abdelmounaïm Allaoui; Bernard Vray
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

Review 7.  Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view.

Authors:  Martin Olivier; David J Gregory; Geneviève Forget
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

8.  CD40-CD40 ligand interactions augment survival of normal mice, but not CD40 ligand knockout mice, challenged orally with Salmonella dublin.

Authors:  I Marriott; E K Thomas; K L Bost
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

Review 9.  CD40 and the immune response to parasitic infections.

Authors:  Carlos S Subauste
Journal:  Semin Immunol       Date:  2009-07-18       Impact factor: 11.130

10.  Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Cristina M Lu; Elaine B Brooks; Richard E Fichtl; Jennifer L DeVecchio; Frederick P Heinzel
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.